The Latest

Tirbanibulin Ointment 1% as a Novel Treatment for Actinic Keratosis: Phase 1 and 2 Results

By December 17, 2020No Comments

Featured Article

Featured Article

Current field-directed treatments of actinic keratosis (AK), a pre-malignant condition, are often limited by severe local reactions and/or complex treatment. Tirbanibulin, a novel potent anti-proliferative synthetic agent that inhibits tubulin polymerization and Src kinase signalling, is being developed as a convenient, safe, and effective field treatment of actinic keratosis.

Read more

Current field-directed treatments of actinic keratosis (AK), a pre-malignant condition, are often limited by severe local reactions and/or complex treatment. Tirbanibulin, a novel potent anti-proliferative synthetic agent that inhibits tubulin polymerization and Src kinase signalling, is being developed as a convenient, safe, and effective field treatment of actinic keratosis.

Steven Kempers MD, Janet DuBois MD, Seth Forman MD, Amy Poon BS MA, Eva Cutler BS BA, Hui Wang PhD, David Cutler MD FRCP(C), Jane Fang MD, Rudolf Kwan MBBS MRCP

 

Actinic keratosis (AK) is a pre-malignant condition, associated with prolonged ultraviolet damage predominantly on the face/scalp, trunk, and extremities. AK affects ~58 million individuals in the US, and typically occurs in males, fair-skinned individuals, and those of advancing age. As the progression of AK to invasive squamous cell carcinoma (iSCC) is unpredictable, the generally accepted approach is to treat all AK.

Current treatments are lesion- or field-directed therapies. Lesion-directed therapies are used when the lesion burden is low; but these modalities can cause scarring and long-term pigmentary changes. Field-directed therapies are used to treat multiple lesions, large areas, and subclinical lesions.

Commonly used topical treatments, while effective, frequently cause moderate-to-severe application-site reactions and deleterious effects on uninvolved skin, which are often considered unacceptable to patients. Moreover, many of these treatments have lengthy or cumbersome dosing regimens that may undermine treatment compliance and compromise efficacy.

Given the disadvantages of available topical therapies, there is a need to develop an agent that has low potential for severe local reactions, effective AK clearance, and convenient dosing.

Read Full Article Now
Article Cited in this Post

You May Also Like

Atopic Dermatitis Philipines

Recommendations for Topical AD Management in the Philippines

| Atopic Dermatitis, Featured Articles, The Latest | No Comments
The prevalence of atopic dermatitis is increasing in Asia, patients have indicated they are not satisfied with disease control; yet, research indicates they are not correctly applying treatments or they…

Oral Tetracyclines and Acne: A Systematic Review for Dermatologists

| Acne, Featured Articles, The Latest | No Comments
Oral tetracyclines are the most widely prescribed systemic antibiotic for acne. Synthesis of efficacy and safety of traditional and novel oral tetracyclines is highly informative to clinical practice. The authors…

Recommendations for Preparing a Disaster Response Plan

| Aesthetics, COVID 19, Featured Articles, The Latest | No Comments
In a paper recently published by JDD, several experts developed a guide based on their own experiences navigating the challenges of this past year. In a paper recently published by…